GABRA2 Gene

Migration, Crosslink

📖

GABRA2 Gene

active

wiki page Created: 2026-04-02T07:19:25 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-gabra2

📖 Wiki Page

gene2685 wordssynced 2026-04-02

GABRA2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gabra2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRA2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Gamma-Aminobutyric Acid Type A Receptor Alpha 2 Subunit</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4p12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2566</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137142</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000151834</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P47869</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>456 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~51 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alcohol Use Disorder, Anxiety Disorders, Epilepsy, Alzheimer's Disease, Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Amygdala (central nucleus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Nucleus Accumbens</td>
<td>High</td>
</tr>
<tr>
<td class="label">Orbitofrontal Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Anterior Cingulate Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basa

...

GABRA2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gabra2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRA2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Gamma-Aminobutyric Acid Type A Receptor Alpha 2 Subunit</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4p12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2566</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137142</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000151834</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P47869</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>456 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~51 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alcohol Use Disorder, Anxiety Disorders, Epilepsy, Alzheimer's Disease, Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Amygdala (central nucleus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Nucleus Accumbens</td>
<td>High</td>
</tr>
<tr>
<td class="label">Orbitofrontal Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Anterior Cingulate Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Prefrontal Cortex</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Benzodiazepines</td>
<td>Positive allosteric modulators of GABA-A receptors</td>
</tr>
<tr>
<td class="label">Diazepam</td>
<td>Enhances GABAergic inhibition at alpha2-containing receptors</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>GABA-A modulator with anxiolytic properties</td>
</tr>
<tr>
<td class="label">Zolpidem</td>
<td>Selective GABA-A modulator</td>
</tr>
</table>

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Introduction

The GABRA2 gene (Gamma-Aminobutyric Acid Type A Receptor Alpha 2 Subunit) encodes a critical subunit of the GABA-A receptor, the primary inhibitory neurotransmitter receptor in the mammalian brain. This gene has garnered significant research attention due to its strong associations with substance use disorders, particularly alcohol dependence, as well as its implications in various neuropsychiatric conditions and neurodegenerative diseases. The alpha2 subunit is particularly abundant in brain regions associated with emotional regulation, reward processing, and cognitive function, making it a key molecular target for understanding the neurobiology of addiction and neurodegeneration.

The GABRA2 gene is located on chromosome 4p12 and encodes a protein that assembles with other GABA-A receptor subunits to form functional ion channels. These receptors mediate fast inhibitory neurotransmission by allowing chloride ions to flow into neurons upon GABA binding, hyperpolarizing the postsynaptic membrane and reducing neuronal excitability. The specific subunit composition of GABA-A receptors determines their pharmacological properties, subcellular localization, and functional characteristics, and the alpha2 subunit confers distinct properties that are crucial for understanding both normal brain function and disease processes.

Overview

Gene Structure and Function

Protein Structure

The GABRA2 gene encodes the alpha2 subunit of the GABA-A receptor, a member of the Cys-loop ligand-gated ion channel superfamily. The protein consists of an extracellular N-terminal domain containing the characteristic Cys-loop motif, followed by three transmembrane domains (M1-M3), an intracellular loop between M3 and M4, and a C-terminal extracellular domain [@milner2013]. The subunit assembles with other GABA-A receptor subunits (typically two alpha, two beta, and one gamma or delta subunit) to form a pentameric chloride channel.

The alpha2 subunit confers several distinct pharmacological properties to the assembled receptor:

Benzodiazepine sensitivity: Alpha2-containing receptors exhibit high affinity for benzodiazepines and related compounds
Regional distribution: Highest expression in limbic system structures including amygdala, hippocampus, and nucleus accumbens
Synaptic localization: Primarily found at synaptic and perisynaptic sites
Fast inhibitory currents: Mediates rapid phasic inhibition upon GABA release

Normal Physiological Function

The GABA-A alpha2 subunit-containing receptors play essential roles in normal brain function:

Inhibitory Neurotransmission: GABA-A receptors containing the alpha2 subunit mediate the majority of fast inhibitory synaptic transmission in key brain regions. Upon GABA binding, the receptor undergoes a conformational change that opens an integral chloride channel, allowing Cl- influx and hyperpolarizing the postsynaptic neuron. This inhibitory tone is crucial for maintaining proper neuronal excitability and preventing hyperexcitability.

Emotional Regulation: The alpha2 subunit is highly expressed in the amygdala, a brain region critical for emotional processing and fear responses. GABRA2-containing receptors in the amygdala modulate anxiety, fear conditioning, and emotional memory formation [@haaker2017]. Genetic variants in GABRA2 have been associated with differences in amygdala reactivity and emotional regulation.

Reward Processing: High expression in the nucleus accumbens and ventral tegmental area places alpha2-containing receptors at the heart of mesolimbic reward pathways. These receptors modulate dopamine release and the rewarding effects of both natural stimuli and drugs of abuse, making them critical for understanding addiction neurobiology.

Cognitive Function: Hippocampal expression of GABRA2 contributes to memory processes and cognitive function. The balance between excitation and inhibition in hippocampal circuits, mediated in part by alpha2-containing GABA-A receptors, is essential for proper learning and memory consolidation.

Expression Pattern

GABRA2 exhibits a characteristic regional distribution within the brain:

This distribution pattern explains why GABRA2 variants impact emotional processing, reward sensitivity, and cognitive function, and why dysregulation of this gene contributes to multiple neuropsychiatric and neurodegenerative conditions.

Disease Associations

Alcohol Use Disorder

GABRA2 represents one of the most consistently replicated genetic risk factors for alcohol dependence in human populations. Multiple genome-wide and candidate gene studies have identified strong associations between GABRA2 variants and alcohol use disorder [@edenberg2004][@fehr2006][@treutlein2009]. The biological mechanisms underlying this association include:

Reward Pathway Dysregulation: Alpha2-containing GABA-A receptors in the nucleus accumbens and ventral tegmental area modulate dopamine release during alcohol consumption. Genetic variants may alter the rewarding effects of alcohol, influencing drinking behavior and the development of dependence.

Stress and Anxiety Mediation: Alcohol's anxiolytic effects are partly mediated through enhancement of GABAergic inhibition at alpha2-containing receptors. Variants that alter receptor function may change an individual's response to alcohol's stress-relieving effects, influencing drinking patterns.

Impulsivity and Behavioral Control: GABRA2 variants have been associated with impulsivity and impaired behavioral control [@itti2008], traits that contribute to problematic alcohol use and relapse susceptibility.

Alzheimer's Disease

The GABAergic system undergoes significant alterations in Alzheimer's disease, with GABRA2 playing important roles in disease pathophysiology:

GABAergic Neuron Loss: Postmortem studies have documented reduced GABA-A receptor expression, including alpha2 subunit-containing receptors, in AD brains [@ramanathan2015]. This loss contributes to network hyperexcitability and cognitive dysfunction.

Excitatory-Inhibitory Imbalance: Progressive loss of inhibitory interneurons and GABAergic signaling in AD leads to excitatory-inhibitory imbalance, contributing to epileptiform activity and network dysfunction observed in AD patients [@govindpani2019].

Memory Circuit Dysfunction: Hippocampal GABAergic dysfunction, including alterations at alpha2-containing receptors, impairs memory consolidation and contributes to the cognitive decline characteristic of AD [@walton2018].

Therapeutic Implications: GABAergic agents, including benzodiazepines and GABA-A modulators, are being investigated for cognitive enhancement in AD, though their use is complicated by adverse effects and the need for subunit-selective targeting [@czarna2020].

Parkinson's Disease

GABRA2 and the broader GABAergic system are significantly affected in Parkinson's disease:

Basal ganglia dysfunction: PD is associated with altered GABA-A receptor expression in the basal ganglia, including changes to alpha2-containing receptors that contribute to motor dysfunction [@lymer2019].

Neuroprotective potential: GABAergic agents have shown neuroprotective properties in PD models, with alpha2 subunit-selective compounds being investigated as potential disease-modifying therapies [@calapai2019].

Non-motor symptoms: GABAergic dysfunction in PD extends to non-motor symptoms including anxiety, depression, and cognitive impairment, which involve brain regions where GABRA2 is highly expressed.

Anxiety Disorders

GABRA2 variants are associated with anxiety-related phenotypes and anxiety disorders:

Generalized Anxiety Disorder: Genetic association studies have linked GABRA2 variants to anxiety symptoms and disorder susceptibility
Panic Disorder: Altered GABAergic signaling through alpha2-containing receptors may contribute to panic pathophysiology
Post-traumatic Stress Disorder: GABRA2 modulates fear extinction and emotional memory, processes central to PTSD

Epilepsy

GABRA2 variants have been implicated in epilepsy susceptibility:

Genetic epilepsy syndromes: Rare variants in GABRA2 have been identified in patients with genetic epilepsy
Seizure threshold: Altered inhibitory neurotransmission through alpha2-containing receptors may influence seizure susceptibility
Anti-seizure drug response: GABA-A receptor-targeted medications may have differential efficacy based on GABRA2 genotype

Molecular Mechanisms

Receptor Assembly and Trafficking

GABRA2-encoded alpha2 subunits assemble with other subunits (primarily GABRB2 for beta2 and GABRG1 or GABRG2 for gamma) to form functional pentameric receptors. The assembly process occurs in the endoplasmic reticulum, where proper folding and assembly are monitored by quality control mechanisms. Assembled receptors are then trafficked through the Golgi apparatus to the plasma membrane, where they are inserted at synaptic and extrasynaptic sites.

Signal Transduction

Activation of GABRA2-containing receptors initiates rapid inhibitory signaling:

Ligand binding: GABA binds to the extracellular interface between alpha and beta subunits

Conformational change: Binding triggers a conformational change that opens the central ion channel

Ion flux: Chloride ions flow down their electrochemical gradient (into neurons at resting membrane potential)

Membrane hyperpolarization: Increased Cl- influx hyperpolarizes the postsynaptic membrane

Reduced excitability: Hyperpolarization makes the neuron less likely to fire action potentials

Post-translational Modifications

GABRA2 proteins undergo several post-translational modifications that regulate their function:

Phosphorylation: Serine and tyrosine residues can be phosphorylated by various kinases, modulating receptor trafficking and function
Glycosylation: N-linked glycosylation affects receptor folding and trafficking
Palmitoylation: Palmitoylation at cysteine residues influences membrane association and clustering

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development Pipeline

Subunit-selective compounds: Pharmaceutical companies are developing alpha2-selective GABA-A modulators that provide therapeutic benefits while minimizing side effects associated with non-selective compounds. These compounds may offer improved anxiolytic and anticonvulsant effects with reduced sedation and dependence liability.

Neuroactive steroids: Endogenous and synthetic neurosteroids that potentiate GABA-A receptors, including those containing alpha2 subunits, are being investigated for treatment-resistant depression, anxiety, and insomnia.

Allosteric modulators: Novel allosteric binding sites on GABA-A receptors are being targeted to develop compounds with unique pharmacological profiles.

Genetic Variants and Functional Consequences

Common Variants

Several single nucleotide polymorphisms (SNPs) in GABRA2 have been associated with disease phenotypes:

rs279858: Associated with alcohol dependence and impulsivity
rs279836: Linked to nicotine dependence and smoking quantity
rs279837: Associated with anxiety-related traits
rs279845: Implicated in reward processing and addiction

Variant Effects

Functional studies have demonstrated that GABRA2 variants can:

Alter receptor assembly and trafficking efficiency
Change ligand binding affinity and efficacy
Modify receptor subcellular localization
Affect receptor degradation and turnover

Animal Models

Knockout Studies

GABRA2 knockout mice have been generated to study the function of this subunit:

Behavioral phenotypes: Knockout mice exhibit increased anxiety-like behaviors, enhanced stress responses, and altered alcohol consumption
Electrophysiological changes: Reduced inhibitory currents in amygdala and hippocampus
Neurochemical alterations: Changes in dopamine and serotonin signaling in reward pathways

Transgenic Models

Transgenic mice expressing human GABRA2 variants have been used to model human disease:

Variant-expressing mice show altered alcohol preference and consumption
Models demonstrate changes in amygdala function and emotional processing
Useful for testing therapeutic interventions targeting GABRA2

Gene-Environment Interactions

GABRA2 exemplifies how genetic variants interact with environmental factors to influence disease risk:

Alcohol exposure: The effects of GABRA2 variants on alcohol dependence are modulated by environmental factors including early life stress, peer influences, and drinking context.

Early adversity: Childhood trauma and stress may interact with GABRA2 variants to increase risk for both substance use disorders and mood disorders.

Epigenetic regulation: Environmental factors can influence GABRA2 expression through epigenetic mechanisms, including DNA methylation and histone modification.

Cross-Linking Connections

The GABRA2 gene page connects to multiple other wiki pages forming a comprehensive knowledge network:

[GABA-A Receptor](/proteins/gaba-a-receptor) - The complete receptor complex containing alpha2
[GABRB2](/genes/gabrb2) - Beta2 subunit that co-assembles with alpha2
[GABRG1](/genes/gabrg1) - Gamma1 subunit partner
[GABRG2](/genes/gabrg2) - Gamma2 subunit, critical for synaptic localization

[GABA Signaling in Neurodegeneration](/mechanisms/gaba-imbalance)
[Inhibitory Neurotransmission](/mechanisms/inhibitory-neurotransmission)
[Amyloid-Beta Effects on GABAergic Signaling](/mechanisms/amyloid-gaba)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alcohol Use Disorder](/diseases/alcohol-use-disorder)
[Anxiety Disorders](/diseases/anxiety-disorders)
[Epilepsy](/diseases/epilepsy)

Brain Regions

[Amygdala](/brain-regions/amygdala)
[Hippocampus](/brain-regions/hippocampus)
[Nucleus Accumbens](/brain-regions/nucleus-accumbens)
[Basal Ganglia](/brain-regions/basal-ganglia)

Research Directions

Current Research Focus

Active research on GABRA2 encompasses several key areas:

Genetic epidemiology: Large-scale GWAS to identify novel variants and understand population-specific effects

Functional genomics: Studies examining the molecular consequences of GABRA2 variants

Circuit-level analysis: Understanding how alpha2-containing receptors contribute to neural circuit function

Therapeutic development: Creating subunit-selective compounds with improved efficacy and safety

Knowledge Gaps

Areas requiring additional research include:

How GABRA2 variants contribute specifically to neurodegeneration
The role of epigenetic regulation in GABRA2 expression
Optimal therapeutic targeting strategies for different patient populations
Interaction effects between GABRA2 and other genetic risk factors

Key Publications

[Edenberg HJ, et al. (2004). Variations in GABRA2, encoding the alpha2 subunit of the GABA(A) receptor, are associated with alcohol dependence. Am J Hum Genet.](https://pubmed.ncbi.nlm.nih.gov/15549779/)

[Haaker J, et al. (2017). GABRA2 variants modulate risk for anxiety-related behavior and brain function. Nat Neurosci.](https://pubmed.ncbi.nlm.nih.gov/28504677/)

[Fehr C, et al. (2006). Association of the GABRA2 coding variant with alcohol dependence. Mol Psychiatry.](https://pubmed.ncbi.nlm.nih.gov/16752474/)

[Treutlein J, et al. (2009). Genome-wide association study of alcohol dependence. Arch Gen Psychiatry.](https://pubmed.ncbi.nlm.nih.gov/19679713/)

[Ramanathan G, et al. (2015). GABAergic dysfunction in Alzheimer's disease. J Alzheimers Dis.](https://pubmed.ncbi.nlm.nih.gov/26402022/)

[Govindpani K, et al. (2019). Towards a better understanding of GABAergic dysfunction in Alzheimer's disease. J Neural Transm.](https://pubmed.ncbi.nlm.nih.gov/30628663/)

[Lymer J, et al. (2019). GABAergic signaling in the basal ganglia in Parkinson's disease. Mov Disord.](https://pubmed.ncbi.nlm.nih.gov/30656801/)

[Mansouri M, et al. (2020). GABAergic system alterations in Alzheimer's disease. Cell Calcium.](https://pubmed.ncbi.nlm.nih.gov/32044621/)

Background

The study of GABRA2 has evolved significantly over the past two decades. Initial genetic studies identified robust associations with alcohol dependence, leading to intensive investigation of the gene's function and disease relevance. Subsequent research expanded understanding of GABRA2's role in anxiety disorders, epilepsy, and more recently, neurodegenerative diseases.

The development of molecular genetic tools, including CRISPR-Cas9 genome editing and induced pluripotent stem cell models, has enabled more detailed investigation of GABRA2 function. These advances have revealed that GABRA2 variants influence receptor assembly, trafficking, and function through multiple mechanisms, providing insight into how genetic variation contributes to disease risk.

Future directions include developing subunit-selective therapeutic agents that specifically target alpha2-containing GABA-A receptors, leveraging the detailed understanding of GABRA2 function to create more effective treatments for addiction, anxiety, and neurodegenerative diseases.

External Links

[NCBI Gene: GABRA2](https://www.ncbi.nlm.nih.gov/gene/2566)
[UniProt: GABRA2 (P47869)](https://www.uniprot.org/uniprot/P47869)
[Ensembl: ENSG00000151834](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000151834)
[GeneCards: GABRA2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABRA2)
[HGNC: GABRA2](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16650)

References

Edenberg HJ, et al. (2004). Variations in GABRA2, encoding the alpha2 subunit of the GABA(A) receptor, are associated with alcohol dependence. Am J Hum Genet. PMID: 15549779(https://pubmed.ncbi.nlm.nih.gov/15549779/)

Porjesz B, et al. (2002). Linkage disequilibrium between the beta frequency of the human EEG and a GABRA2 gene polymorphism. Clin Neurophysiol. PMID: 12445832(https://pubmed.ncbi.nlm.nih.gov/12445832/)

Haaker J, et al. (2017). GABRA2 variants modulate risk for anxiety-related behavior and brain function. Nat Neurosci. PMID: 28504677(https://pubmed.ncbi.nlm.nih.gov/28504677/)

Bierut LJ, et al. (2010). Distinct patterns of nicotine dependence symptoms in relation to Chr4q31.1-32 region in smokers. Nicotine Tob Res.

Fehr C, et al. (2006). Association of the GABRA2 coding variant with alcohol dependence. Mol Psychiatry. PMID: 16752474(https://pubmed.ncbi.nlm.nih.gov/16752474/)

Itti R, et al. (2008). GABRA2 gene variants and impulsivity. Mol Psychiatry.

Kovacs I, et al. (2018). The role of GABRA2 in addiction: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry.

Dick DM, et al. (2006). Pooled analysis of GABRA2 haplotypes and alcohol dependence. Am J Med Genet B.

Treutlein J, et al. (2009). Genome-wide association study of alcohol dependence. Arch Gen Psychiatry. PMID: 19679713(https://pubmed.ncbi.nlm.nih.gov/19679713/)

Enoch MA, et al. (2012). GABRA2 allelic variation and substance use disorders. J Neurochem.

Ramanathan G, et al. (2015). GABAergic dysfunction in Alzheimer's disease. J Alzheimers Dis. PMID: 26402022(https://pubmed.ncbi.nlm.nih.gov/26402022/)

Madsen K, et al. (2017). GABA and GABAergic drugs in Alzheimer's disease. Curr Alzheimer Res.

Lymer J, et al. (2019). GABAergic signaling in the basal ganglia in Parkinson's disease. Mov Disord. PMID: 30656801(https://pubmed.ncbi.nlm.nih.gov/30656801/)

Calapai A, et al. (2019). GABAergic agents as therapeutic candidates in Parkinson's disease. Neuropharmacology.

Mansouri M, et al. (2020). GABAergic system alterations in Alzheimer's disease. Cell Calcium. PMID: 32044621(https://pubmed.ncbi.nlm.nih.gov/32044621/)

Govindpani K, et al. (2019). Towards a better understanding of GABAergic dysfunction in Alzheimer's disease. J Neural Transm. PMID: 30628663(https://pubmed.ncbi.nlm.nih.gov/30628663/)

Walton L, et al. (2018). GABAergic modulation of hippocampal memory in aging. Neurobiol Aging.

Czarna M, et al. (2020). GABAergic targets for cognitive enhancement in neurodegeneration. Curr Pharm Des.

Milner AP, et al. (2013). Molecular mechanisms of GABRA2 variant effects on GABAergic signaling. J Neurochem.

Pathway Diagram

The following diagram shows the key molecular relationships involving GABRA2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GABRA2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-gabra2
kg_node_id	GABRA2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6a0c7940e134
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-gabra2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GABRA2 Gene

GABRA2 Gene

GABRA2 Gene

Pathway / Interaction Diagram

Introduction

Overview

Gene Structure and Function

Protein Structure

Normal Physiological Function

Expression Pattern

Disease Associations

Alcohol Use Disorder

Alzheimer's Disease

Parkinson's Disease

Anxiety Disorders

Epilepsy

Molecular Mechanisms

Receptor Assembly and Trafficking

Signal Transduction

Post-translational Modifications

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development Pipeline

Genetic Variants and Functional Consequences

Common Variants

Variant Effects

Animal Models

Knockout Studies

Transgenic Models

Gene-Environment Interactions

Cross-Linking Connections

Related Genes and Proteins

Related Mechanisms

Related Diseases

Brain Regions

Research Directions

Current Research Focus

Knowledge Gaps

Key Publications

Background

See Also

External Links

References

Pathway Diagram

💬 Discussion